Navigation Links
Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Date:11/22/2011

the incidence of serious adverse events generally well-balanced across the placebo and ARCALYST groups.  Injection site reactions, usually considered mild, were reported more commonly with ARCALYST than with placebo.  A third study, RE-SURGE, evaluated the safety of ARCALYST in patients who were at risk for gout flares because they were initiating or taking uric acid-lowering drug treatment.  This study showed that ARCALYST was generally well tolerated and the safety profile was consistent with that reported in the PRE-SURGE 1 and PRE-SURGE 2 studies.

About the Phase 3 ARCALYST Program in GoutIn the PRE-SURGE 1 and PRE-SURGE 2 studies, 488 patients were randomized to receive one of the following treatment regimens: ARCALYST 160 milligrams (mg) as an initial subcutaneous loading dose followed by weekly 80mg subcutaneous injections for 16 weeks, or ARCALYST 320mg as an initial subcutaneous loading dose followed by weekly 160mg subcutaneous injections for a total of 16 weeks, or subcutaneous weekly placebo injections for 16 weeks.

The North American PRE-SURGE 1 (PREventative Study against URate lowering drug-induced Gout Exacerbations) study was a double-blind, placebo-controlled study which evaluated the number of gout flares per patient over the first 16 weeks following initiation of allopurinol therapy.  Patients who received ARCALYST (rilonacept) at a weekly, self-administered, subcutaneous dose of 160mg had an 80% decrease in mean number of gout flares (p<0.0001) and patients receiving the 80mg dose had a 73% decrease compared to the placebo group (p<0.0001).

Overall in PRE-SURGE 1, the cumulative rate of infections was 17.3% in patients treated with ARCALYST 160mg, 18.8% in patients treated with ARCALYST 80mg, and 22.8% in placebo patients.  No deaths were reported in this study.

The global PRE-SURGE 2 (PREventative Study against URate-lowering
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
2. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
6. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
7. Regeneron Reports Second Quarter 2011 Financial and Operating Results
8. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
9. Trading in Regeneron Common Stock Halted
10. Regeneron Reports First Quarter 2011 Financial and Operating Results
11. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 In today,s increasingly ... web presence to reflect the needs of a ... must meet the needs of key stakeholders while ... According to recent research by benchmarking ... the participating companies averaged more than $100,000 in ...
(Date:12/19/2014)... 2014 Radiology information system ... used to store, manipulate, and distribute patient radiological ... tracking and scheduling system, result reporting, and an ... HIS and other databases improves the hospital workflow. ... scheduling, patient list management, radiology department workflow management, ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... Precision and Reduce High Failure Rates in Central ... 16 ICON (Nasdaq: ICLR ) ... to the pharmaceutical, biotechnology and medical device industries ... patient evaluation, today announced that they have signed ...
... Patients on corticosteroids are one-third less likely to ... taking statin medicationsStudy is first in a series ... medicationsFRANKLIN LAKES, N.J., March 14 Results of ... Meeting of the American Academy of Asthma, Allergy ...
Cached Medicine Technology:ICON and MedAvante Sign Alliance Agreement 2New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits 2New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits 3New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits 4
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... Parker & Sons, Inc. a focused and dedicated ... contractor services announces reaching a milestone by providing 40 ... Arizona. Parker and Sons is comprised of a reliable ... customer service the number one priority. The company was ... one service vehicle and has since grown to become ...
(Date:12/19/2014)... December 19, 2014 Sub Zero Ice Cream ... a blood drive Sunday the 28th from 2pm-6pm at the ... Sawyer Road in Sarasota, FL. , Inquiries regarding time slots ... for participating in the donating process, Sub Zero Ice Cream ... frozen, custom ice cream. , About Sub Zero Ice Cream ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... News) -- New research warns parents that buying an older car ... Nearly half of teen drivers killed in the United States between ... years old and often lacked important safety features that are available ... drivers killed in crashes were in cars at least six years ... 31 percent were in cars 11 to 15 years old, and ...
Breaking Medicine News(10 mins):Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Older Cars a Bad Choice for Younger Drivers 2
... after a gap of 22 years, the World Health Organisation ... three-year-old Somali child at Dadaab refugee camp in northeast Kenya. ... had reported outbreak of polio cases in 2005, according to ... Fadela Chaib said the successful control of polio worldwide would ...
... of chemotherapy patients has increased the demand for blood components. ... ,According to the Irish Blood Transfusion Service and the Irish ... a 50% increase in the demand for blood components due ... can be met by over 22,000 donations of platelets every ...
... called IRF6 is involved in the common birth defect cleft ... J. and// Lucille A. Carver College of Medicine and their ... findings, published online Oct. 15 in Nature Genetics, reveal an ... skin cells, a discovery that may have implications for wound ...
... The two recent government-sponsored reports released on Tuesday revealed ... the risks due to contamination. These reports// are based ... major health outcomes among adults, the benefits of eating ... been lost on the public," said Dr. Dariush Mozaffarian, ...
... been approved for its treatment by the FDA, following ... chemotherapy with// Taxotere survived an average of 11.4 months ... standard drugs. ,The drug will be used ... in locally advanced squamous cell head and neck cancer. ...
... is no more restricted to just risk groups alone in ... each day according to statistics with almost one percent of ... is alarming to note that like Africa, which has the ... is now common through even heterosexual contact China too has ...
Cached Medicine News:Health News:Chemotherapy increases the demand for blood components 2Health News:Gene Involved In Common Birth Defect Also Regulates Skin Biology 2Health News:Gene Involved In Common Birth Defect Also Regulates Skin Biology 3Health News:Eating Fish has more Benefits than Risks 2
... Triad Plus PVP-I Prep Gel ... PVP-I Prep Gel is film forming, ... action that has been known to ... gram-positive bacteria (including antibiotic resistant), fungi, ...
... HIBICLENS bonds with ... a protective, germ-killing field. ... fast acting antimicrobial effect, ... irritation potential promotes compliance ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Medicine Products: